Funder: Melanoma Research Alliance
Due Dates: April 10, 2026: Letter of Intent (LOI) | June 16, 2026: Full application
Funding Amounts: $100,000–$500,000 (preclinical/pre-IND); up to $1,000,000 (clinical trials); up to 3 years, milestone-based payments
Summary: Supports preclinical to clinical-stage research advancing innovative cellular and vaccine therapies for acral and uveal melanoma.
Key Information: LOI required; applications from academic/nonprofit institutions worldwide; no for-profit applicants.